Page 52 - Human Use News Today

EQS-News: PAION AG / Key word(s): Half Year ResultsPAION AG reports financial results for the First Half-Year 2023 30.08.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.PAION AG reports financial results for the First Half-Year 2023   Byfavo® approval by European Commi...

Paris , 25 October 2018 - Ipsen , a global specialty-driven biopharmaceutical group, today announced sales for the third quarter of 2018. Financial highlights ...

EQS-News: PAION AG / Key word(s): Half Year Results PAION AG reports financial results for the First Half-Year 202...

InflaRx N.V. (IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, Wednesday said the European Medicines Agency or EMA has validated its Marketing Authorization Application or MAA for Vilobelimab to treat Critically Ill COVID-19 Patients.

Pfizer Inc. and BioNTech SE said Wednesday that its updated COVID-19 vaccine, which is tailored to the new Omicron XBB.1.5 variant has been recommended to...

By Colin Kellaher Pfizer and BioNTech have won key European regulatory backing for an updated version of their Comirnaty Covid-19 vaccine that targets a...

 The updated COVID-19 vaccine is tailored to the Omicron XBB.1.5 sublineage of SARS-CoV-2 and is recommended for individuals 6 months of age and older Recommendation based on pre-clinical data...

Approval based on progression-free survival benefit demonstrated in Phase 3 KEYNOTE-811 trial KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient...

The European Commission has approved pembrolizumab for use in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic, HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 with a combined positive score of at least 1.

Korea Biomedical Review reported that Celltrion has finalised an agreement with Johnson & Johnson (J&J) permitting Celltrion to launch CT-P43, its…